Fear, Courage, Grit: Meet More Than 50 ‘Hospital Heroes’ – WTOP

They Arent Backing Down The pandemic has dealt a massive blow to the country and world. Front-line health care workers

They Arent Backing Down

The pandemic has dealt a massive blow to the country and world. Front-line health care workers from coast to coast have gone above and beyond the call of duty pushing further in the face of fear than anyone can imagine. Many dont consider themselves heroes some even bristle at the word but U.S. News is chronicling their experiences, along with their hopes, fears and the lessons theyre learning during this historic year. In the slides ahead youll meet a nurse who came out of retirement to work alongside her daughter, a physician treating patients in the hard-hit Navajo Nation and so many more. These are U.S. News Hospital Heroes.

Dr. Rana Awdish

A critical care doctor on the front lines at Henry Ford Health System in Detroit, Awdish prepared herself, her family and her team for the inevitable hit from the virus. And it hit hard. Drawing on her experience as a patient on a ventilator after her own life-threatening medical emergency in 2008, she found herself in a unique position to understand the fear, pain and loneliness that her patients with COVID-19 were feeling at a personal level. Read her entire story.

Anticipating that kind of trauma will never protect you from it.

Father Chris Ponnet

Father Ponnets work as director of spiritual care at LAC+USC Medical Center brings end-of-life peace to patients and to their families, especially during the coronavirus pandemic, when loved ones are unable to be present at the end. He does his best to make patients feel seen while cataloging as much as he can of his time to share with the patients family. He wears an N95 mask, goggles, a face shield and a disposable gown and gloves to minister to these patients. Read his entire story.

My role is to be a bridge between the family and the patient, Ponnet says. I want to capture as much of what is happening in the room as possible, to report to the family.

Esbeda Refugio

Making the choice to continue her work as a custodian at LAC+USC Medical Center in the midst of the novel coronavirus pandemic was not an easy one for Refugio. As a single mom of four children, she worried about bringing the virus home. However, her sense of duty to both the patients and the other hospital employees ultimately made the decision for her. Donning PPE, Refugio cleans two to three COVID rooms a shift, though she treats all rooms as if the patients were COVID-positive given the infectious nature of the disease. Read her entire story.

Its my responsibility to protect others, not only when it comes to patient care, but also the doctors, the nurses and the respiratory techs who go into the room, she says. I want everybody to be safe, so I clean to the best of my ability.

Patrick OConnor

OConnor isnt a doctor or nurse, but his role is no less essential. When the pandemic first landed at LAC+USC Medical Center, OConnor, supervisor of the carpentry shop at the hospital, worked with his team to make adjustments to intubation boxes placed over patients who need a tube inserted to help them breathe. The original boxes didnt provide enough coverage for doctors and nurses exposed to a patients infectious respiratory droplets as they performed the procedure. His team also built rooms for donning and doffing PPE in a safe environment. Read his entire story.

Were in the background, doing things to make things safer for the doctors, nurses and other health care workers and staffers, he says. Thats why were here.

Dr. Josh Mugele

As New York City became the coronavirus epicenter, Mugele, an emergency medicine physician in Georgia, felt it was his duty to help in any way he could. This, for him, meant boarding a plane and heading straight into the line of fire, volunteering at one of the citys hard-hit public hospitals. While there, he treated many patients, including one of the hospitals own nurses whod fallen ill with COVID-19. One of his goals was to learn as much as he could about how best to treat COVID-19, so he could bring those lessons back to his hometown hospital. By the time he returned to Georgia, cases were climbing sharply. Read his story.

This is going to take a long time, he says. Were going to have to change the way we live, the way we practice medicine and the way we make policies for years to come.

Jody Mugele

Before Mugeles husband, Dr. Josh Mugele, left to volunteer on the COVID-19 front lines in New York, the couple went through what they call the death document. A ritual they started before Dr. Mugeles disaster medicine fellowship in Liberia in 2013 during the Ebola outbreak, the document contains anything she may need in the case of his death, along with letters he wrote to her and their two kids. He was gone for nearly a month before safely returning. Read her story.

It really was the loneliest I think Ive ever felt, says Jody. I was talking to the dogs like theyre my best friends.

Jeanette Trella

Back in February, when calls started trickling into the Poison Control Call Center Trella manages at the Childrens Hospital of Philadelphia, she knew it was just the beginning. Her team is usually the first to hear about medical emergencies before they grow bigger. Sensing then that COVID-19 would pick up steam, she raced to launch the Greater Philadelphia Coronavirus Help Line, which has helped advise callers on everything from symptoms to economic woes tied to the pandemic. Read her entire story.

We often get calls about dangerous trends right when theyre starting.

Dr. Steven Brown

For 20 nights a month, Brown monitors as many as 100 patients a night virtually from a command station now in his living room. A pulmonologist for Mercy Virtual Care Center, he helps on-the-ground clinicians like nurses and respiratory therapists care for patients with COVID-19, often in rural areas that need support and guidance. Through his screens he has made tough decisions and seen many people die once, three in one hour. However, he is hopeful that once researchers discover more about the virus weak spots, a vaccine will be created. Read his story.

If we listen to scientists, accept facts and make educated decisions based on the best available data, we will be able to drive down the number of cases of COVID-19.

Mary Beth Patterson

Patterson thought shed left her days as a nurse behind her when she retired over a year ago to move to New Hampshire. But when Stony Brook University Medical Center, her old stomping grounds and the same hospital where her daughter works as a nurse, started seeing an influx in COVID-positive patients, she made the decision to come out of retirement to help. Read her story.

I just felt compelled to come back to work and be alongside my daughter during this pandemic.

Kelly Patterson

When her mom made the decision to come out of retirement and return to nursing during the pandemic, Kelly Patterson was initially nervous. A young nurse at Stony Brook Medical Center, just a few years out of school, Patterson worried that her moms age would be a risk factor. During the height of the crisis, she was glad to have her moms knowledge of patient care and empathy skills more important now than ever. Though they work opposite shifts Kelly at night and her mom during the day she stops by to see her at the beginning and end of each shift. Read Kellys entire story.

Youre seeing death almost every shift, Kelly says. Its not a soothing, comfortable death. Theyre not accompanied by their loved ones, not able to see them or talk to them. Its very sad.

Felix Khusid

A veteran respiratory therapist at New York Presbyterian Brooklyn Methodist, Khusid sees patients at the terrifying height of the disease, when they feel like their lungs are filled with water. His job then becomes to do whatever he can to help them stay alive, ideally without a ventilator. This sometimes includes high-flow therapy, which pushes concentrated levels of oxygen into the body and helps patients breathe on their own for longer. Read his entire story.

During this epidemic, what was really emphasized I think for the whole world is the expert job that the respiratory therapists are doing, he says. Its a profound responsibility that has profound consequences.

Dr. Gregg Rosner

Rosners experience as a cardiac intensivist at New York Presbyterian/Columbia University Medical Center didnt necessarily prepare him to treat patients with a disease that primarily attacks the lungs. However, when the pandemic struck his hospital, he stepped up to lead the COVID-19 intensive care unit. In the beginning, the ICU team faced many unknowns, including how best to wear PPE to protect themselves. Rosner set the tone for his new team. I couldnt be scared. I couldnt be unsure, he says. We had a team with an impossible task and I was amazed at how everyone in the hospital stepped up. Read his story.

The coronavirus affected everyone of all races and all ages; people who were sick before and people who werent sick before, Rosner says.

Erica Harris

Erica Harris has been a nurse at NYC Health + Hospitals Elmhurst in Queens for 20 years, and shes never seen anything like the novel coronavirus before. Harris leads the hospitals COVID-19 testing tent which, at opening hour, rarely sees lines of fewer than 15 to 20 people, mostly the working-class immigrants her hospital serves. The outdoor tent met the overwhelming need for increased testing and took teamwork to create the negative pressure rooms inside it that keep virus particles from flowing everywhere. Read her entire story.

Once you faced the challenge and the last two months have been a challenge you feel stronger on the other side.

Dr. Vonzella Bryant

One of Bryants first COVID-positive patients at Boston Medical Center came in with an oxygen level of 75% far outside the normal range of 95% to 100%. In an effort to prevent intubation, Bryant, an emergency medicine physician, turned him over onto his stomach, a technique called proning. Luckily, the patients levels went back up to normal. Bryant and her family may have seen one of the earlier cases of the virus at home when her mother, who lives with the family, returned from vacation with telltale symptoms. After recovering and quarantining for 14 days, her mother now takes care of Bryants two kids, as Bryant juggles work on the front lines. Read her full story.

At the hospital, we were being hit all at once with sick, agitated and sometimes combative patients; scared and nervous essential workers; staff with underlying conditions who were afraid of getting the virus; and we were fearful that wed run out of ICU space.

Dr. Yinan Lan

When coronavirus patients started flooding into NYC Health + Hospitals Bellevue, Lan, a primary care physician, knew from her already extensive work with the homeless population in the city that things would be even worse for those who lived in shelters or on the streets. Her team set up a system to keep track of patients and ensure they have a place to stay, enough food and medication, and are as healthy as possible especially during this time of uncertainty. Read her story.

When theres a will to do that, it takes everyone not just a city agency, not just a few nonprofit organizations or hospitals.

Bre Loughlin

One-half of the nursing duo that developed virtual coronavirus screening for the single womens shelter at the Salvation Army Dane County in Madison, Wisconsin, Loughlin came up with the idea when she visited a mens shelter and talked to workers. They described the challenges in screening guests for the virus, including the gap in knowledge of lay volunteers who werent equipped to properly screen for the disease. With the help of donated tablets, a Wi-Fi hotspot and volunteer nurses, the first virtual screening at the shelter began. Read Loughlins entire story.

We had to think about at what point we would bring people into the trailer, maintain distancing, where we would place the PPE. All of that was part of the design of the screening we were able to pop up in 48 hours.

Tracy Zvenyach

The other half of the nursing duo that developed virtual screening for homeless shelters in Madison, Wisconsin, Zvenyach has seen a lot of grateful people come through the testing centers, especially since the team makes it a priority to guarantee housing for the night no matter the outcome of the test. Read her entire story.

One of the most daunting things about the pandemic is that, while we have our essential front-line workers, theres this enormous secondary front line in the community.

Dr. Dominic Carollo

Carollo, an anesthesiologist at Ochsner Medical Center in Louisiana, knows firsthand what his COVID-19 patients endure. Almost a week after he started working in the COVID intensive care ward, he developed a dry cough. Hed caught the virus. When his symptoms started to get scary, he relied on his medical training and buckled up for a one-on-one battle with COVID-19. I put an IV in and I gave myself 2 liters of fluid, he says. Almost two weeks later, his symptoms were gone and he went right back to treating patients. Read Carollos full story.

Every COVID shift that I could work is one less exposure for one of my colleagues.

Dr. Kyle Annen

In March, Annen, the medical director of transfusion services and patient blood management at Childrens Hospital Colorado, received a call about a critically ill adult patient with COVID-19, whose family urgently wanted their loved one to get a transfusion of convalescent plasma. They had heard that plasma from people who had recovered from COVID-19 may help. Other centers werent equipped to snap into action, so Annens team raced to launch a massive effort. In only a few weeks, they collected enough plasma donations for more than 150 patients. Read Annens entire story.

I think people who had COVID want to help, Annen says. They feel its a way they can make a direct impact to help someone who had it worse than they did.

Jessica Hawks

When the pandemic hit the U.S., the Pediatric Mental Health Institute at Childrens Hospital Colorado stopped offering in-person visits to prevent the spread of COVID-19. So Hawks, the clinical director of outpatient services, and her team pivoted to provide behavioral health care via telehealth to ensure kids with everything from eating disorders to depression didnt experience a lapse in care. Though there were privacy concerns and technology barriers to contend with, Hawks and her teammates got the program up and running. Read her story.

It was very clear that (telehealth services) was something wed need to offer to our patients and their families during this stressful time.

Pat Givens

As PPE shortages plague hospitals, Pat Givens, the chief nursing executive at Childrens Hospital Colorado, and her colleagues developed a system to track gear such as N95 masks and gowns. Their work ensured that even amidst a global shortage, the hospital would not run out of protective necessities. Read Givens entire story.

Because of our early tracking and conservation measures, we never ran out. Weve been able to sustain our PPE throughout the pandemic.

Rubiela Guzman

Guzman heads up a team of 43 patient transporters at Mount Sinai Hospital. Theyre charged with moving patients quickly and safely from place to place. When the pandemic engulfed New York City, their role turned somber: wheeling patients who didnt survive COVID-19 onto refrigerated trucks when the morgue became full. Read Guzmans entire story.

The hardest part was just dealing with the overwhelming amount of patients that were passing away, Guzman says. And understanding that this was real. This is not a drill. This is not a movie,

Jessica Montanaro

Montanaro, the assistant nursing coordinator at Mount Sinai Morningside, knew emergencies like the back of her hand after years working in the hospitals medical-trauma intensive care unit. In March, however, the numbers of patients coming into her department were unlike anything shed seen before. Still, she found herself uniquely prepared for COVID-19. For the past few years, her team has been perfecting the proning technique, now widely used to help COVID patients in serious respiratory distress. Read her story.

What I was seeing, what I was experiencing, you couldnt process it. You just had to keep moving.

Christopher Wilkinson

When his manager in the bone marrow transplant unit came to Wilkinson and his colleagues to enlist them in a new program at Mount Sinai that would give gravely ill COVID-19 patients an experimental stem cell therapy, Wilkinson volunteered immediately. Though dangerous, the possibility of helping the sickest patients drew him in. The trial has shown early promise in COVID patients Wilkinson is a member of the first team in the country to use this treatment. Read his entire story.

Yes, its dangerous. Yes, we have to be careful [] I felt like it was my duty to help.

Dr. Joseph Herrera

Before COVID-19, he was a thriving sports medicine doctor. When confronted with the deadly virus, Herrera, chair of the department of rehabilitation at Mount Sinai Health System, and his department transitioned their unit into a 90-bed COVID care space. Herrera was nervous: He hadnt worked a ventilator in almost 20 years. So, he spent every waking hour not at work studying everything he could to prepare for all the unknowns. The disease was fierce, taking the lives of many patients. He worries about the safety of his wife, an anesthesiologist on the front lines in New Jersey, and his medical residents, who were redeployed to hard-hit hospitals around the city. Read his entire story.

Its just heartbreaking to hear the fear and the exhaustion and the grieving they are going through. He says: Our young doctors. Our future.

Dr. Jonathan Ramin

Ramin, a fourth-year physical rehabilitation and medicine resident at Mount Sinai, volunteered to redeploy at one of New York Citys hardest hit public hospitals. He had never experienced anything like the COVID-19 ICU. He cared for otherwise healthy people his own age and didnt know if they would live or die. However, fear often leads to hope Ramin has used his training to help rehabilitate patients recovering from the new disease. Read his full story.

Sometimes, no matter what we did for these patients no matter how young they were, no matter how healthy they were, they werent immune to this.

Dr. Michael Bell

Bell, chief of critical care medicine at Childrens National, didnt believe for a second that the novel coronavirus didnt affect children, which was rumored in the early days. Since the pandemic began, he and his team have worked around the clock, treating more than 275 kids and young adults with COVID-19. When kids started coming to the hospital with symptoms of a new mystery syndrome seemingly linked to COVID-19, his team was ready. As multisystem inflammatory syndrome (MIS-C) continued to affect children, Bell worked with teams across the country and the world to discover more. Read his story.

Its important to talk to every hospital we can find every hour of the day so we can collaborate and share information with them. We need lots of people to keep looking at it, to keep reporting it basically in real time.

Anna Stroman

When the pandemic hit Maryland, Anna Stroman, a chaplain with Doctors Community Hospital, immediately recognized a need to provide hospital employees with an outlet for stress. She created a virtual prayer line for stretched-thin front-line workers to call for a listening ear or uplifting prayer. Doctors and nurses also email in prayer requests for their seriously ill patients with COVID-19. With strict visitor restrictions in place, Stroman has found it difficult to not be able to comfort patients at their bedside. Read her full story.

Just this whole season of not being able to personally go into a patients room and sit there and talk with them is difficult. Most times, patients just want you to listen.

Diondre McBride

Though still a trainee through the Healthcare Chaplains Ministry Association, McBride is determined to pray over patients even if hes swathed in PPE and behind a barrier. Although he cannot be at their bedside, he remains committed to providing peace and light to patients, their families and hospital staff during this unprecedented time. Read his full story.

They asked me: Was I willing to put myself at risk to be chaplain during this COVID-19? I said, This is what I do. And Ive been doing it ever since.

Dr. Stephen Kates

Running out of PPE, especially N95 masks, was one of the main issues that Kates and a committee of colleagues at VCU Health in Virginia set out to address when the virus hit their hospital. Kates, chair of orthopedic surgery, used his metalworking hobby to come up with a heavy duty metal shelf that would hold a high volume of masks to allow for mass disinfection with high-intensity ultraviolet light. The system has sterilized 20,000 masks, which means the hospital hasnt run out of this necessary protective gear. Read his story.

Im happy to be able to help others with this, he says. Thats why I went into medicine, to help others.

Dr. Neal Shipley

Soon after COVID-19 flooded New York City closing many doctors offices Shipley, medical director of 52 Northwell Health-GoHealth Clinics, saw an influx of patients with fevers, upper respiratory distress and fatigue. In response, he and his staff developed a system for knowing when to send patients home, when to treat them and when to send them to the emergency room. In the first two months of the pandemic, a third of the approximately 20,000 patients coming into the urgent care centers tested positive for COVID-19. Shipleys urgent care centers are seeing high demand for both virus and antibody testing. Read his story.

When theres a second wave, if we dont have a better strategy for testing and contact tracing, I worry that all of the sacrifice will be for naught and we will be right back where we started.

Rev. Kris Pikaart

Rev. Kris Pikaart, a hospital chaplain in Gallup, New Mexico, has never worked harder than during her hours and days spent in the COVID unit. Many of the hospitals patients are residents of the Navajo Nation a community thats been hit hard by the virus, largely due to the widespread lack of running water and other resources. Pikaart, who has only taken a few days off since March, offers comfort to patients and their families, doing what she can to make this unprecedented time less awful and lonely. Read her entire story.

I have a goal that nobody here dies alone, ever, Pikaart says. I cant always make that happen because this disease is funny and its not always predictable how deaths from the disease are sometimes they happen so quickly.

Ashley Holsman

See the article here:
Fear, Courage, Grit: Meet More Than 50 'Hospital Heroes' - WTOP

GMP Cell Banking Services Market: Subsequent demand for stem cell therapies would provide a major boost to the market – BioSpace

Global GMP Cell Banking Services Market: Overview

A burgeoning pharmaceutical industry hard-pressed to find treatments and cures for various chronic and other ailments has given rise to the concept of cell banking. With limited capacity to store cells required for research in the field of regenerative medicines, somatic cell therapy, gene therapy, and tissue-engineered products they are increasingly outsourcing it to other entities specializing in it.

Read Report Overview - http://www.transparencymarketresearch.com/gmp-cell-banking-services-market.html

GMP basically stands for Good Manufacturing Practice. A recent report on GMP cell banking services finds that the market is set to rise in the near term with the capacity constraints being faced by the pharmaceutical manufacturing companies and medical research institutes.

An upcoming report on the global GMP cell banking services market by Transparency Market Research attempts to examine in depth the factors molding it. It studies both the market specific factors and macro fundamentals stoking or hindering market growth. The report also segments the GMP cell banking services market based on different parameters such as applications and geography. It then deep dives into each sector to understand which ones hold out maximum promise. The report also tries to figure out the current and future size of the market with respect to revenue generation.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=50559

Global GMP Cell Banking Services Market: Key Trends

A cell bank comprises of a storage facility for cells extracted from different body fluids and organ tissue so that they can be used in the future. Stored cells contain detailed characterization of the cell line thereby decreasing chances of cross contamination. And GMP cell banking services consists of outsourcing gathering, storing, characterization, and testing facilities of cell lines, tissues, and cells. The report predicts that the rising popularity and subsequent demand for stem cell therapies would provide a major boost to the global GMP cell banking services market.

As per the TMR report, the global GMP cell banking services market is also being boosted by the development of cutting-edge preservation technologies and surging research in cell line development. However, complexity of the entire procedure and inconsistent demand is dampening market growth to an extent.

Request for Analysis of COVID19 Impact on GMP Cell Banking Services Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=50559

Depending upon the cell type, the global GMP cell banking services market can be segmented into microbial, mammalian, yeast, insect, stem cell, and avian, among others. Among them, the segment of mammalian currently has a significant share in the market. It generates most of the revenue and would probably rise at a healthy clip in the years to come. Meanwhile, the microbial segment is predicted to emerge as the most attractive in the upcoming years.

Global GMP Cell Banking Services Market: Regional Outlook

The global GMP cell banking services market is spread across North America, Europe, Asia Pacific, and the Middle East and Africa. North America, among them, is considered one of the attractive GMP cell banking services market with the mammalian cell type segment generating most of the revenue. The segment has also been generating substantial revenue in the Asia Pacific GMO cell banking services market. In fact, the Asia Pacific market is seeing solid rise because of the shift of research and development activities in the region from North America and Europe.

Pre Book GMP Cell Banking Services Market Research - https://www.transparencymarketresearch.com/checkout.php?rep_id=50559&ltype=S

Global GMP Cell Banking Services Market: Competitive Dynamics

The global GMP cell banking services market is fragmented in nature. This is because of the presence of several companies offering a range of services in it. This also limits their global outreach and localizes competition. Some the key players among them profiled in the report include WuXi AppTec, Eurofins Scientific, Charles River Laboratories International, Inc., Lonza Group Ltd., and SGS Ltd.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Mr. Rohit Bhisey Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: https://www.transparencymarketresearch.com/

The rest is here:
GMP Cell Banking Services Market: Subsequent demand for stem cell therapies would provide a major boost to the market - BioSpace

Global Stem Cell Therapy Market 2020 Trends, Market Share, Industry Size, Opportunities, Analysis And Forecast To 2026 – Cole of Duty

Stem Cell Therapy Market 2020

Wiseguyreports.Com AddsStem Cell TherapyCovid-19 Impact On Global Market Growth, Opportunities, Analysis Of Top Key Players And Forecast To 2025To Its Research Database.

Report Summary:

The purpose of the report is to provide a comprehensive and detailed analysis for the industryStem Cell Therapy. The report takes 2020 as the base year and considers a wide range of factors affecting the industry to provide a forecast still the year 2026. The information provided by the report can be used by industry and market analysts as well as by people who have an interest in the industry. The data used in the report is reliable and accurate. Primary and secondary research has been conducted to collect the data. The data in the report has been analysed using a wide range of mathematical and statistical metrics so as to provide the users of the report with quantifiable numbers that can be used to compare the performance of the industry with others of the same type. Methods like Price Trend Analysis. SWOT, Porters 5 Forces have been made use to prepare the report and give a reliable analysis of the industry.

This report presents a comprehensive overview, market shares and growth opportunities of Stem Cell Therapy market by type, application, key companies and key regions.

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3. Osiris Therapeutics NuVasive JCR Pharmaceutical Pharmicell Chiesi Pharmaceuticals Molmed Medi-post Takeda (TiGenix) Anterogen

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Request Free Sample ReportStem Cell Therapy industry outlook @https://www.wiseguyreports.com/sample-request/5022982-global-stem-cell-therapy-market-growth-status-and-outlook-2020-2025

This study considers the Stem Cell Therapy value generated from the sales of the following segments:

Segmentation by type: breakdown data from 2015 to 2020 in Section 2.3; and forecast to 2025 in section 10.7.Autologous Allogeneic

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2025 in section 10.8.Musculoskeletal Disorder Wounds & Injuries Cornea Cardiovascular Diseases Others

For More Details@http://heraldkeeper.com/news/covid-19-impact-on-global-stem-cell-therapy-market-2020-industry-analysis-size-share-growth-trends-forecast-to-2025-485424.html

If you have any special requirements, please let us know and we will offer you the report as you want.

Major Key Points from Table of Content:

1 Scope of the Report1.1 Market Introduction 1.2 Research Objectives 1.3 Years Considered 1.4 Market Research Methodology 1.5 Economic Indicators 1.6 Currency Considered

2 Executive Summary 2.1 World Market Overview 2.1.1 Global Stem Cell Therapy Market Size 2015-2025 2.1.2 Stem Cell Therapy Market Size CAGR by Region 2.2 Stem Cell Therapy Segment by Type 2.2.1 Autologous 2.2.2 Autologous 2.3 Stem Cell Therapy Market Size by Type 2.3.1 Global Stem Cell Therapy Market Size Market Share by Type (2015-2020) 2.3.2 Global Stem Cell Therapy Market Size Growth Rate by Type (2015-2020) 2.4 Stem Cell Therapy Segment by Application 2.4.1 Musculoskeletal Disorder 2.4.2 Wounds & Injuries 2.4.3 Cornea 2.4.4 Cardiovascular Diseases 2.4.5 Others 2.5 Stem Cell Therapy Market Size by Application 2.5.1 Global Stem Cell Therapy Market Size Market Share by Application (2015-2020) 2.5.2 Global Stem Cell Therapy Market Size Growth Rate by Application (2015-2020)

3 Global Stem Cell Therapy by Players 3.1 Global Stem Cell Therapy Market Size Market Share by Players 3.1.1 Global Stem Cell Therapy Market Size by Players (2018-2020) 3.1.2 Global Stem Cell Therapy Market Size Market Share by Players (2018-2020) 3.2 Global Stem Cell Therapy Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion

4 Stem Cell Therapy by Regions 4.1 Stem Cell Therapy Market Size by Regions 4.2 Americas Stem Cell Therapy Market Size Growth 4.3 APAC Stem Cell Therapy Market Size Growth 4.4 Europe Stem Cell Therapy Market Size Growth 4.5 Middle East & Africa Stem Cell Therapy Market Size Growth

5 Americas 5.1 Americas Stem Cell Therapy Market Size by Countries 5.2 Americas Stem Cell Therapy Market Size by Type 5.3 Americas Stem Cell Therapy Market Size by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Key Economic Indicators of Few Americas Countries

6 APAC 6.1 APAC Stem Cell Therapy Market Size by Regions 6.2 APAC Stem Cell Therapy Market Size by Type 6.3 APAC Stem Cell Therapy Market Size by Application 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 Key Economic Indicators of Few APAC Regions

7 Europe 7.1 Europe Stem Cell Therapy by Countries 7.2 Europe Stem Cell Therapy Market Size by Type 7.3 Europe Stem Cell Therapy Market Size by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 7.9 Spain 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa 8.1 Middle East & Africa Stem Cell Therapy by Countries 8.2 Middle East & Africa Stem Cell Therapy Market Size by Type 8.3 Middle East & Africa Stem Cell Therapy Market Size by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries

9 Market Drivers, Challenges and Trends 9.1 Market Drivers and Impact 9.1.1 Growing Demand from Key Regions 9.1.2 Growing Demand from Key Applications and Potential Industries 9.2 Market Challenges and Impact 9.3 Market Trends

10 Global Stem Cell Therapy Market Forecast 10.1 Global Stem Cell Therapy Market Size Forecast (2021-2025) 10.2 Global Stem Cell Therapy Forecast by Regions 10.2.1 Global Stem Cell Therapy Forecast by Regions (2021-2025) 10.2.2 Americas Market Forecast 10.2.3 APAC Market Forecast 10.2.4 Europe Market Forecast 10.2.5 Middle East & Africa Market Forecast 10.3 Americas Forecast by Countries 10.3.1 United States Market Forecast 10.3.2 Canada Market Forecast 10.3.3 Mexico Market Forecast 10.3.4 Brazil Market Forecast 10.4 APAC Forecast by Countries 10.4.1 China Market Forecast 10.4.2 Japan Market Forecast 10.4.3 Korea Market Forecast 10.4.4 Southeast Asia Market Forecast 10.4.5 India Market Forecast 10.4.6 Australia Market Forecast 10.5 Europe Forecast by Countries 10.5.1 Germany Market Forecast 10.5.2 France Market Forecast 10.5.3 UK Market Forecast 10.5.4 Italy Market Forecast 10.5.5 Russia Market Forecast 10.5.6 Spain Market Forecast 10.6 Middle East & Africa Forecast by Countries 10.6.1 Egypt Market Forecast 10.6.2 South Africa Market Forecast 10.6.3 Israel Market Forecast 10.6.4 Turkey Market Forecast 10.6.5 GCC Countries Market Forecast 10.7 Global Stem Cell Therapy Forecast by Type 10.8 Global Stem Cell Therapy Forecast by Application

11 Key Players Analysis 11.1 Osiris Therapeutics11.1.1 Company Details 11.1.2 Stem Cell Therapy Product Offered 11.1.3 Osiris Therapeutics Stem Cell Therapy Revenue, Gross Margin and Market Share (2018-2020) 11.1.4 Main Business Overview 11.1.5 Osiris Therapeutics News 11.2 NuVasive11.2.1 Company Details 11.2.2 Stem Cell Therapy Product Offered 11.2.3 NuVasive Stem Cell Therapy Revenue, Gross Margin and Market Share (2018-2020) 11.2.4 Main Business Overview 11.2.5 NuVasive News 11.3 JCR Pharmaceutical11.3.1 Company Details 11.3.2 Stem Cell Therapy Product Offered 11.3.3 JCR Pharmaceutical Stem Cell Therapy Revenue, Gross Margin and Market Share (2018-2020) 11.3.4 Main Business Overview 11.3.5 JCR Pharmaceutical News 11.4 Pharmicell11.4.1 Company Details 11.4.2 Stem Cell Therapy Product Offered 11.4.3 Pharmicell Stem Cell Therapy Revenue, Gross Margin and Market Share (2018-2020) 11.4.4 Main Business Overview 11.4.5 Pharmicell News 11.5 Chiesi Pharmaceuticals11.5.1 Company Details 11.5.2 Stem Cell Therapy Product Offered 11.5.3 Chiesi Pharmaceuticals Stem Cell Therapy Revenue, Gross Margin and Market Share (2018-2020) 11.5.4 Main Business Overview 11.5.5 Chiesi Pharmaceuticals News 11.6 Molmed11.6.1 Company Details 11.6.2 Stem Cell Therapy Product Offered 11.6.3 Molmed Stem Cell Therapy Revenue, Gross Margin and Market Share (2018-2020) 11.6.4 Main Business Overview 11.6.5 Molmed News 11.7 Medi-post11.7.1 Company Details 11.7.2 Stem Cell Therapy Product Offered 11.7.3 Medi-post Stem Cell Therapy Revenue, Gross Margin and Market Share (2018-2020) 11.7.4 Main Business Overview 11.7.5 Medi-post News 11.8 Takeda (TiGenix)11.8.1 Company Details 11.8.2 Stem Cell Therapy Product Offered 11.8.3 Takeda (TiGenix) Stem Cell Therapy Revenue, Gross Margin and Market Share (2018-2020) 11.8.4 Main Business Overview 11.8.5 Takeda (TiGenix) News 11.9 Anterogen11.9.1 Company Details 11.9.2 Stem Cell Therapy Product Offered 11.9.3 Anterogen Stem Cell Therapy Revenue, Gross Margin and Market Share (2018-2020) 11.9.4 Main Business Overview 11.9.5 Anterogen News

Continued..

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

[emailprotected]

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Go here to read the rest:
Global Stem Cell Therapy Market 2020 Trends, Market Share, Industry Size, Opportunities, Analysis And Forecast To 2026 - Cole of Duty

Pompe Disease Treatment Market Trends, Demand, Global Analysis and Forecast to 2030 – Cole of Duty

Market Highlights

Global Pompe Disease Treatment Marketis expected to register aCAGR of3.0% during the forecast period and expected to hitUSD 1,664.9 Million by 2030.

Pompe disease is a genetic metabolic disorder that occurs in infants. This disease is caused due to the mutations in the GAA gene responsible for producing the acid, alpha-glucosidase enzyme that converts glycogen into a simple form. The absence or mutation in the GAA gene leads to the accumulation of glycogen and results to have a heart problem, muscle weakness, liver damage that can lead to premature death in the new-born.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/8233

Theincreasing government initiatives and rising R&D activities by manufacturersto find new solutions for the diagnosis and treatment of Pompe diseaseareanticipated to drive the global Pompe disease treatment market growth. However, the high cost of treatment is expected to restrict market growth to a certain extent.

Segment Analysis

The global Pompe disease treatment market has been divided based on type, therapy, and end-user.

The market, based on type, has been segregated into late-onset Pompe disease, classic infantile-onset Pompe disease, and non-classic infantile-onset Pompe disease.

Based on therapy, the Pompe disease treatment market has been divided intoenzyme replacement therapy (ERT), gene therapy, and others.

On the basis of end-user, the market is bifurcated into hospitals & clinics and research & academic institutes.

Regional Analysis

The global Pompe disease treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is likely to hold the largest share of the global Pompe disease treatment market during the assessment period. This largest share can be attributed to the presence of established payers and an increase in the number of patients with Pompe disease in the region. The American region is a hub for major market players such as Genzyme Corporation, Audentes Therapeutics, and Amicus Therapeutics, Inc operating in the Pompe disease treatment market, which eventually drives the growth of the regional market. Additionally, the growing awareness among the general population regarding the available treatments for Pompe disease is projected to boost the regional market growth during the review period.

Europe is the second-largest market for Pompe disease treatment owing to factors such as the growing research and development initiatives, support by the governments in the healthcare sector, and improvement in reimbursement policies. For instance, European countries are extremely cautious and have implemented the newborn screening (NBS) program as a means of early detection and identification of severe illnesses in newborns, including Pompe disease.

Asia-Pacific is estimated to be the fastest-growing region in the global market due to the increasing healthcare expenditure, growing awareness among patients regarding rare disorders, and expanding healthcare industry. The Pompe disease treatment market in the Middle East & Africa is expected to witness gradual growth due to the significantly grow owing to the growing awareness about the treatment of rare diseases and developing healthcare infrastructure.

Key Players

MRFR recognizes the following companies as theKey Players in the Global Pompe Disease Treatment MarketAmicus Therapeutics, Inc (US) Sanofi (France), Audentes Therapeutics (US), Oxyrane (UK), Valerion Therapeutics (US), AVROBIO, Inc. (US), CENTOGENE AG (UK),and others.

Key Findings of the Study

Access Report Details @https://www.marketresearchfuture.com/reports/pompe-disease-treatment-market-8233

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [emailprotected]

Follow this link:
Pompe Disease Treatment Market Trends, Demand, Global Analysis and Forecast to 2030 - Cole of Duty

Human Embryonic Stem Cells (HESC) Market 2020by Manufacturers, Dealers, Consumers, Revenue, Regions, Types, Applications and Forecast to 2026 – Cole…

Inquire or Share Your Questions If Any before the Purchasing This Report https://www.absolutereports.com/enquiry/pre-order-enquiry/15170257

This report focuses on the global Human Embryonic Stem Cells (HESC) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Human Embryonic Stem Cells (HESC) development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The study objectives of this report are:

Table of Contents of Human Embryonic Stem Cells (HESC) Market:

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Human Embryonic Stem Cells (HESC) Revenue

1.4 Market Analysis by Type

1.4.1 Global Human Embryonic Stem Cells (HESC) Market Size Growth Rate by Type: 2020 VS 2026

1.4.2 Type 1

1.4.3 Type 2

1.5 Market by Application

1.5.1 Global Human Embryonic Stem Cells (HESC) Market Share by Application: 2020 VS 2026

1.5.2 Application 2

1.5.3 Application 2

1.6 Study Objectives

1.7 Years Considered

Purchase this Report (Price 2900 USD for A Single-User License) at https://www.absolutereports.com/purchase/15170257

2 Global Growth Trends by Regions

2.1 Human Embryonic Stem Cells (HESC) Market Perspective (2015-2026)

2.2 Human Embryonic Stem Cells (HESC) Growth Trends by Regions

2.2.1 Human Embryonic Stem Cells (HESC) Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Human Embryonic Stem Cells (HESC) Historic Market Share by Regions (2015-2020)

2.2.3 Human Embryonic Stem Cells (HESC) Forecasted Market Size by Regions (2021-2026)

2.3 Industry Trends and Growth Strategy

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Challenges

2.3.4 Porters Five Forces Analysis

2.3.5 Human Embryonic Stem Cells (HESC) Market Growth Strategy

2.3.6 Primary Interviews with Key Human Embryonic Stem Cells (HESC) Players (Opinion Leaders)

3 Competition Landscape by Key Players

3.1 Global Top Human Embryonic Stem Cells (HESC) Players by Market Size

3.1.1 Global Top Human Embryonic Stem Cells (HESC) Players by Revenue (2015-2020)

3.1.2 Global Human Embryonic Stem Cells (HESC) Revenue Market Share by Players (2015-2020)

3.1.3 Global Human Embryonic Stem Cells (HESC) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Human Embryonic Stem Cells (HESC) Market Concentration Ratio

3.2.1 Global Human Embryonic Stem Cells (HESC) Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Human Embryonic Stem Cells (HESC) Revenue in 2019

3.3 Human Embryonic Stem Cells (HESC) Key Players Head office and Area Served

3.4 Key Players Human Embryonic Stem Cells (HESC) Product Solution and Service

3.5 Date of Enter into Human Embryonic Stem Cells (HESC) Market

3.6 Mergers & Acquisitions, Expansion Plans

Continued..

Contact Us:

Name: Ajay More

Phone: US +1424 253 0807/ UK +44 203 239 8187

Email id- [emailprotected]

Our Other Reports:

Vehicle Diesel Engine Market Size 2020 Global Technology, Development, Trends and Forecasts to 2024

Zeolite Market Size Growth Opportunities, Driving Factors by Manufacturers, Regions, Type and Application, Revenue Market Forecast 2024

Water Tank Market Size 2020 Global Leading Players, Industry Updates, Future Growth, Business Prospects, Forthcoming Developments and Future Investments by Forecast to 2024

Global Wheelchair Cushion Market Size 2020 by Manufacturers, Regions, Type and Application, Forecast to 2024

Marine Composites Industry Size 2020 by Manufactures Types, Applications, Regions and Forecast to 2024

The rest is here:
Human Embryonic Stem Cells (HESC) Market 2020by Manufacturers, Dealers, Consumers, Revenue, Regions, Types, Applications and Forecast to 2026 - Cole...

New material mimics strength, toughness of mother of pearl – Science Codex

In the summer, many people enjoy walks along the beach looking for seashells. Among the most prized are those that contain iridescent mother of pearl (also known as nacre) inside. But many beachcombers would be surprised to learn that shimmery nacre is one of nature's strongest, most resilient materials. Now, researchers reporting in ACS Nano have made a material with interlocked mineral layers that resembles nacre and is stronger and tougher than previous mimics.

Some mollusks, such as abalone and pearl oysters, have shells lined with nacre. This material consists of layers of microscopic mineral "bricks" called aragonite stacked upon alternating layers of soft organic compounds. Scientists have tried to replicate this structure to make materials for engineering or medical applications, but so far artificial nacre has not been as strong as its natural counterpart. Hemant Raut, Caroline Ross, Javier Fernandez and colleagues noticed that prior nacre mimics used flat mineral bricks, whereas the natural material has wavy bricks that interlock in intricate herringbone patterns. They wanted to see if reproducing this structure would create a stronger, tougher nacre mimic for sustainable medical materials.

Using the components of natural nacre, the team made their composite material by forming wavy sheets of the mineral aragonite on a patterned chitosan film. Then, they interlocked two of the sheets together, filling the space between the wavy surfaces with silk fibroin. They stacked 150 interlocked layers together to form a composite that was about the thickness of a penny. The material was almost twice as strong and four times as tough as previous nacre mimics -- close to the strength and toughness reported for natural nacre. The artificial nacre was also biocompatible, which the researchers demonstrated by culturing human embryonic stem cells on its surface for one week. These features suggest that the material could be suitable for sustainable, low-cost medical uses, the researchers say.

Read more from the original source:
New material mimics strength, toughness of mother of pearl - Science Codex

Recombinant Human Growth Hormone Market Size, Share 2020 Industry Demand, Trends, Regional Overview, Top Manufacture, Business Growth and Forecast to…

Some of the key questions answered in this report:

Global Recombinant Human Growth Hormone Market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and instrumentation and downstream demand analysis is additionally dispensed. The Global Recombinant Human Growth Hormone market development trends and marketing channels are analyzed. Finally, the feasibility of latest investment projects is assessed and overall analysis conclusions offered.

Purchase this report (Price 2900 USD for a single-user license) https://www.industryresearch.biz/purchase/15098328

Years considered for this report:

With tables and figures helping analyse worldwide Global Recombinant Human Growth Hormone market trends, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Some Points from TOC:

1 Recombinant Human Growth Hormone Market Overview 1.1 Product Overview and Scope of Recombinant Human Growth Hormone 1.2 Recombinant Human Growth Hormone Segment by Type 1.2.1 Global Recombinant Human Growth Hormone Production Growth Rate Comparison by Type 2020 VS 2026 1.2.2 Type 1 1.2.3 Type 2 1.2.4 Others 1.3 Recombinant Human Growth Hormone Segment by Application 1.3.1 Recombinant Human Growth Hormone Consumption Comparison by Application: 2020 VS 2026 1.3.2 Application 1 1.3.3 Application 2 1.3.4 Application 3 1.3.5 Other 1.4 Global Recombinant Human Growth Hormone Market by Region 1.5 Global Recombinant Human Growth Hormone Growth Prospects 1.5.1 Global Recombinant Human Growth Hormone Revenue Estimates and Forecasts (2015-2026) 1.5.2 Global Recombinant Human Growth Hormone Production Capacity Estimates and Forecasts (2015-2026) 1.5.3 Global Recombinant Human Growth Hormone Production Estimates and Forecasts (2015-2026)

2 Market Competition by Manufacturers 2.1 Global Recombinant Human Growth Hormone Production Capacity Market Share by Manufacturers (2015-2020) 2.2 Global Recombinant Human Growth Hormone Revenue Share by Manufacturers (2015-2020) 2.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.4 Global Recombinant Human Growth Hormone Average Price by Manufacturers (2015-2020) 2.5 Manufacturers Recombinant Human Growth Hormone Production Sites, Area Served, Product Types 2.6 Recombinant Human Growth Hormone Market Competitive Situation and Trends

3 Production Capacity by Region 4 Global Recombinant Human Growth Hormone Consumption by Regions

5 Production, Revenue, Price Trend by Type5.1 Global Recombinant Human Growth Hormone Production Market Share by Type (2015-2020) 5.2 Global Recombinant Human Growth Hormone Revenue Market Share by Type (2015-2020) 5.3 Global Recombinant Human Growth Hormone Price by Type (2015-2020) 5.4 Global Recombinant Human Growth Hormone Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

6 Global Recombinant Human Growth Hormone Market Analysis by Application 6.1 Global Recombinant Human Growth Hormone Consumption Market Share by Application (2015-2020) 6.2 Global Recombinant Human Growth Hormone Consumption Growth Rate by Application (2015-2020)

7 Company Profiles and Key Figures in Recombinant Human Growth Hormone Business 7.1 Company Profile 1 7.1.1 Company Profile 1 Recombinant Human Growth Hormone Production Sites and Area Served 7.1.2 Recombinant Human Growth Hormone Product Introduction, Application and Specification 7.1.3 Company Profile 1 Recombinant Human Growth Hormone Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.1.4 Main Business and Markets Served

7.2 Company Profile 2 7.2.1 Company Profile 2 Recombinant Human Growth Hormone Production Sites and Area Served 7.2.2 Recombinant Human Growth Hormone Product Introduction, Application and Specification 7.2.3 Company Profile 2 Recombinant Human Growth Hormone Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.2.4 Main Business and Markets Served

7.3 Company Profile 3 7.3.1 Company Profile 3 Recombinant Human Growth Hormone Production Sites and Area Served 7.3.2 Recombinant Human Growth Hormone Product Introduction, Application and Specification 7.3.3 Company Profile 3 Recombinant Human Growth Hormone Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.3.4 Main Business and Markets Served

7.4 Company Profile 4 7.4.1 Company Profile 4 Recombinant Human Growth Hormone Production Sites and Area Served 7.4.2 Recombinant Human Growth Hormone Product Introduction, Application and Specification 7.4.3 Company Profile 4 Recombinant Human Growth Hormone Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.4.4 Main Business and Markets Served

7.5 Company Profile 5 7.5.1 Company Profile 5 Recombinant Human Growth Hormone Production Sites and Area Served 7.5.2 Recombinant Human Growth Hormone Product Introduction, Application and Specification 7.5.3 Company Profile 5 Recombinant Human Growth Hormone Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.5.4 Main Business and Markets Served

7.6 Company Profile 6 7.6.1 Company Profile 6 Recombinant Human Growth Hormone Production Sites and Area Served 7.6.2 Recombinant Human Growth Hormone Product Introduction, Application and Specification 7.6.3 Company Profile 6 Recombinant Human Growth Hormone Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.6.4 Main Business and Markets Served .. 8 Recombinant Human Growth Hormone Manufacturing Cost Analysis 8.1 Recombinant Human Growth Hormone Key Raw Materials Analysis 8.1.1 Key Raw Materials 8.1.2 Key Raw Materials Price Trend 8.1.3 Key Suppliers of Raw Materials 8.2 Proportion of Manufacturing Cost Structure 8.3 Manufacturing Process Analysis of Recombinant Human Growth Hormone 8.4 Recombinant Human Growth Hormone Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers 9.1 Marketing Channel 9.2 Recombinant Human Growth Hormone Distributors List 9.3 Recombinant Human Growth Hormone Customers

10 Market Dynamics 10.1 Market Trends 10.2 Opportunities and Drivers 10.3 Challenges 10.4 Porters Five Forces Analysis

11 Production and Supply Forecast 11.1 Global Forecasted Production of Recombinant Human Growth Hormone (2021-2026) 11.2 Global Forecasted Revenue of Recombinant Human Growth Hormone (2021-2026) 11.3 Global Forecasted Price of Recombinant Human Growth Hormone (2021-2026) 11.4 Global Recombinant Human Growth Hormone Production Forecast by Regions (2021-2026) 11.4.1 North America Recombinant Human Growth Hormone Production, Revenue Forecast (2021-2026) 11.4.2 Europe Recombinant Human Growth Hormone Production, Revenue Forecast (2021-2026) 11.4.3 China Recombinant Human Growth Hormone Production, Revenue Forecast (2021-2026) 11.4.4 Japan Recombinant Human Growth Hormone Production, Revenue Forecast (2021-2026)

12 Consumption and Demand Forecast 13 Forecast by Type and by Application (2021-2026) 14 Research Finding and Conclusion 15 Methodology and Data Source

.Continued

Detailed TOC of Global Recombinant Human Growth Hormone Market @ https://www.industryresearch.biz/TOC/15098328

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. Industry Research is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Info:

Name: Mr. Ajay More

E-mail: [emailprotected]

Organization: Industry Research Biz

Phone: US +1424 253 0807 / UK +44 203 239 8187

Our Other Reports:

Amifostine Market Size 2020 Global Manufacturing Size, Share, Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2024

Adsorption Dryer Market 2020 Global Industry Trends, Future Growth, Regional Overview, Market Share, Size, Revenue, and Forecast Outlook till 2024

Human Embryonic Stem Cells (HESC) Market Size 2020 Worldwide Industry Trends, Share, Gross Margin, Future Demand, Analysis by Top Leading Player and Forecast till 2026, Says Industry Research Biz

Pivalaldehyde Market Size 2020 Industry Share, Trends Evaluation, Global Growth, Recent Developments, Latest Technology, and 2026 Future Forecast Research Report

High Carbon Spring Steel Wire Market Size 2020 Growing Rapidly with Modern Trends, Development Status, Investment Opportunities, Share, Revenue, Demand and Forecast to 2026 Says Industry Research Biz

See the rest here:
Recombinant Human Growth Hormone Market Size, Share 2020 Industry Demand, Trends, Regional Overview, Top Manufacture, Business Growth and Forecast to...

Adipose Derived Stem Cell Therapy Market: Demand, Insights, Analysis, Opportunities, Segmentation and Forecast to 2026 – 3rd Watch News

Adipose Derived Stem Cell Therapy Market Report 2020-2026 incorporates a complete examination of the current market. The report begins with the fundamental Adipose Derived Stem Cell Therapy industry review and afterward goes into every single detail.

Adipose Derived Stem Cell Therapy Market Report contains inside and out data on significant producers, openings, difficulties, and industry patterns and their effect available gauge. Adipose Derived Stem Cell Therapy Market additionally gives information about the organization and its activities. This report additionally gives data on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the organization.

Adipose Derived Stem Cell Therapy Market competition by top manufacturers/players, with Adipose Derived Stem Cell Therapy sales volume, Price (USD/Unit), Revenue (Million USD) and Market Share for each manufacturer/player; the top players including BioRestorative Therapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., Cytori Therapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCells Biotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc., Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, among others.

We do offer a sample of this report. Kindly go through the following information in order to access sample copy.

Ask for Sample Copy of the Report: @ https://www.coherentmarketinsights.com/insight/request-sample/2357

This Report Sample Includes :

Brief Introduction to the research report. Table of Contents (Scope covered as a part of the study) Top players in the market Research framework (presentation) Research methodology adopted by Coherent Market Insights

Significant Features that are under contribution and key features of the report:

1) What all territorial division secured? Will the particular nation of intrigue be included? At present, the examination report gives unique consideration and spotlight on the accompanying districts: North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain and so on), South America (Brazil, Argentina and so on) and Middle East and Africa (Saudi Arabia, South Africa and so on) ** One nation of explicit intrigue can be incorporated at no additional expense. For consideration of progressively local portion, the statement may fluctuate.

2) What all organizations are right now profiled in the report? The report Contain the Major Key Players right now profiled in this market. ** List of organizations referenced may differ in the last report subject to Name Change/Merger and so on.

3) Can we include or profiled a new organization according to our needs? Indeed, we can include or profile a new organization according to customer need in the report. Last affirmation to be given by the exploration group contingent on the trouble of the study. ** Data accessibility will be affirmed by research if there should be an occurrence of a secretly held organization. Up to 3 players can be included at no additional expense.

4) Can the consideration of extra Segmentation/Market breakdown is conceivable? Indeed, the incorporation of extra division/Market breakdown is conceivable to dependent upon information accessibility and trouble of the overview. Notwithstanding, a point by point necessity should be imparted to our examination before giving last affirmation to the customer. ** Depending upon the prerequisite the deliverable time and statement will differ.

Adipose Derived Stem Cell Therapy Market Dynamics on the planet primarily, the overall 2019-2026 Adipose Derived Stem Cell Therapy Market is dissected across major worldwide locales. CMI likewise gives tweaked explicit local and national level reports for the accompanying regions.

Region Segmentation:

North America (the USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Columbia etc.) The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Table of Contents

Report Overview:It includes the Kkk market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Kkk market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Kkk market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Kkk market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Key questions answered in the report:

1. What will the market development pace of Adipose Derived Stem Cell Therapy market in 2026 2. What are the key components driving the worldwide Adipose Derived Stem Cell Therapy market 3. Who are the key makers in Adipose Derived Stem Cell Therapy market space? 4. What are the market openings, showcase hazard and market diagram of the Adipose Derived Stem Cell Therapy market? 5. What are deals, income, and value investigation by types and uses of Adipose Derived Stem Cell Therapy market? 6. What are deals, income, and value examination by locales of Adipose Derived Stem Cell Therapy industry?

Research onlyprovidesa Table of Contents (ToC), Scope of the reportandresearch framework of the report.

Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2357

In this study, the years considered to estimate the market size of 2018-2026 Adipose Derived Stem Cell Therapy Market are as follows: History Year: 2015-2017 Base Year: 2017 Estimated Year: 2018 Forecast Year 2018 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. Raj Shah Phone: US +12067016702 / UK +4402081334027 Email: [emailprotected]

See original here:
Adipose Derived Stem Cell Therapy Market: Demand, Insights, Analysis, Opportunities, Segmentation and Forecast to 2026 - 3rd Watch News

Cell Proliferation Kit Market: Facts, Figures and Analytical Insights, 2019 to 2025 – Cole of Duty

In 2018, the market size of Cell Proliferation Kit Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2018 to 2025 as the forecast period to estimate the market size for Cell Proliferation Kit .

This report studies the global market size of Cell Proliferation Kit , especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2626680&source=atm

This study presents the Cell Proliferation Kit Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Cell Proliferation Kit history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

The report firstly introduced the Cell Proliferation Kit basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The major players profiled in this report include: Biological Industries Thermo Fisher Scientific Sigma-Aldrich (Merck) BD Biosciences GE Healthcare PerkinElmer Millipoore (Merck) Bio-Rad Biotium Mindray Medical

The end users/applications and product categories analysis: On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into- Colorimetric Detection Method Fluorescent Detection Method

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Cell Proliferation Kit for each application, including- Clinical Industrial & Applied Science Stem Cell Research

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2626680&source=atm

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Cell Proliferation Kit product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Cell Proliferation Kit , with price, sales, revenue and global market share of Cell Proliferation Kit in 2017 and 2018.

Chapter 3, the Cell Proliferation Kit competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Cell Proliferation Kit breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2626680&licType=S&source=atm

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Cell Proliferation Kit market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Cell Proliferation Kit sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Go here to read the rest:
Cell Proliferation Kit Market: Facts, Figures and Analytical Insights, 2019 to 2025 - Cole of Duty

Edited Transcript of HMED.ST earnings conference call or presentation 16-Jul-20 12:00pm GMT – Yahoo Finance

Jul 16, 2020 (Thomson StreetEvents) -- Edited Transcript of Hansa Biopharma AB earnings conference call or presentation Thursday, July 16, 2020 at 12:00:00pm GMT

Kempen & Co. N.V., Research Division - Research Analyst

Ladies and gentlemen, welcome to the Hansa Biopharma AB Interim Report for January to June 2020. (Operator Instructions)

Today, I'm pleased to present CEO, Soren Tulstrup. Speaker, please begin.

Thank you, operator. Good afternoon to those of you in Europe, and good morning to those in the U.S. Welcome to the Hansa Biopharma conference call to discuss the results for the first half of the year of 2020. I'm Soren Tulstrup, CEO of Hansa Biopharma. With me today, I have our CFO, Donato Spota; as well as our Head of Investor Relations, Klaus Sindahl.

Today, we'll review the overall progress and highlights of the business as well as near-term milestones. Our presentation should take 15 minutes. And after that, we'll take your questions.

Now please turn to Slide 2. Please allow me to draw your attention to our forward-looking statements, which apply to this presentation.

Please turn to Slide 3. Hansa Biopharma's evolution into a fully integrated, commercial-stage biopharmaceutical company has taken a major step forward with the recent achievement of 2 landmark milestones. On June 25, we received a positive opinion from the CHMP of the European Medicines Agency for imlifidase in highly sensitized kidney patients in the European Union. We're very excited about this recognition from the CHMP. The positive opinion by the CHMP and the expected launch of imlifidase towards the end of this year brings hope to the thousands of highly sensitized patients across Europe, waiting for a life-saving kidney transplant and will take Hansa Biopharma a major step forward to becoming a commercial-stage biopharmaceutical company. A week later, on July 2, we announced the achievement of another landmark milestone, namely the exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as a potential pretreatment prior to the administration of gene therapy for Duchenne muscular dystrophy and limb-girdle muscular dystrophy in patients with neutralizing antibodies to adeno-associated virus.

We're very excited to partner with Sarepta, a leading player in the field to use the unique features of imlifidase to potentially enable gene therapy treatment in patients, who today aren't eligible for these breakthrough therapies, due to preexisting neutralizing antibodies. The agreement with Sarepta also serves as a validation of our enzyme technology as we expand beyond transplantation and acute autoimmune diseases.

Last weekend, we raised SEK 1.1 billion or approximately USD 121 million in an overnight placement of new ordinary shares to fund our R&D programs and commercial buildup. The placing received strong interest from leading life science investors in the U.S. and Europe and was multiple times oversubscribed. In the U.S., the proposed study protocol for a randomized controlled trial in kidney transplant was submitted to the FDA on June 17. Once the protocol is formally approved, we expect to set up the specific trial centers in the U.S. and apply for the necessary ethical approvals. Recruitment of the first patient is targeted for the fourth quarter of this year.

While we have, overall, been able to maintain a high level of productivity despite the impact from the COVID-19 pandemic, patient recruitment into the ongoing AMR and GBS Phase II studies has been delayed, as the decision was taken to temporarily suspend recruitment and no patients were thus enrolled during the second quarter. As communicated earlier, the impact from the pandemic is therefore expected to extend recruitment time lines by 3 to 6 months. Currently, we expect to reinitiate enrollment in both studies during the third quarter. In the anti-GBM Phase II study, we completed enrollment in the investigator sponsored program back in January this year, and we expect the first data readout in the third quarter, as indicated earlier.

Lastly, I also want to highlight how we continue to build a high-performance organization, while adding both capacity and new competencies. In June, we announced the recruitment of Professor Achim Kaufhold, as Chief Medical Officer. Professor Kaufhold brings extensive experience as a senior leader in immunology, infectious diseases and oncology and will support the company's expansion outside transplantation. This morning, we also announced the appointment of Katja Margell, as our new Head of Corporate Communications. Katja brings extensive experience from strategic, corporate and capital markets communication for leading communications agencies and companies and will be a great addition to the Hansa team. Katja will assume her new role effective immediately.

Now please turn to Slide 4. As I said earlier, we are very excited to have received a positive opinion from the CHMP. This brings hope to thousands of highly sensitized patients across Europe, waiting for a life-saving kidney transplant and takes Hansa Biopharma one important step closer to becoming a commercial-stage biopharmaceutical company. The decision by the CHMP further served to validate the potential of Hansa Biopharma's proprietary drug development engine to develop approvable immunomodulatory drug candidates for rare and serious diseases and comes at a time when we are significantly expanding our activities into autoimmune diseases, gene therapy and oncology.

More specifically, CHMP recommends conditional approval of imlifidase for the desensitization treatment of highly sensitized, adult kidney transplant patients with a positive cross-match against an available disease donor. The positive opinion from the CHMP comes on the back of a 16-month repeat process by EMA, and the recommendation is based on data from 4 completed Phase II studies with imlifidase and kidney transplantation across Sweden, France and the U.S. Throughout the review process, imlifidase was supported by EMA's Priority Medicines Scheme, which provides early and enhanced scientific and regulatory support to medicines that have a particular potential to address patients' unmet medical needs. Adoption of the positive opinion by the European Commission is expected in the third quarter of 2020. As communicated earlier, our immediate goal remains to launch imlifidase in the first clinics in the fourth quarter of this year.

Our launch strategy will be focused on leading kidney transplantation centers with the potential to become early adopters and centers of reference. A post-approval study will run in parallel with the launch and will be an additional way for key clinics to get experience with imlifidase.

Please turn to Slide 5. In the U.S., we submitted the proposed study protocol for the randomized controlled study with imlifidase in kidney transplant to the FDA on June 17. We aim to commence recruitment in Q4 2020, following receipt of the necessary approvals and the initiation of trial centers in the U.S. However, we acknowledge the risk of a potential timeline impact due to the COVID-19 pandemic, which is affecting priority setting by the FDA in clinics. The proposed new trial would include 45 patients with a cPRA score of 99.9% or above at 10 to 15 centers in the U.S. eGFR, which is a measure for kidney function, will be used as a circuit endpoint after 12 months to demonstrate a clinical benefit of imlifidase therapy versus patients being waitlisted.

The results from this new clinical study could support a BLA filing in the U.S. by 2023 under the accelerated approval pathway as communicated earlier. Obviously, we'll do what we can to compress the process and timeline as much as possible.

Please turn to Slide 6. If we look beyond transplantation, patient recruitment into the ongoing AMR and GBS Phase II studies has been negatively impacted by the COVID-19 pandemic, due to a temporary suspension of patient recruitment. No patients were involved during the second quarter. End of the second quarter, 4 of the targeted 30 patients have been enrolled in each of the respective studies. As communicated earlier, the impact from the pandemic is expected to delay recruitment timelines for these studies by 3 to 6 months. We expect to reinitiate enrollment in both studies in the third quarter this year, and enrollment in the AMR and GBS studies is now expected to be completed in the first and second half of 2021, respectively. In the anti-GBM Phase II study, we completed enrollment in the investigator sponsored program, back in January this year, and we expect the first data readout in the third quarter, as stated previously.

Please turn to Slide 7 and a summary overview of our pipeline. As depicted on this overview slide, thanks to the continued progress over the past years, we have now developed a broad clinical pipeline in both transplantation and autoimmune diseases, and we have exciting preclinical projects ongoing in cancer and antidrug antibodies, augmented shortly by the initiation of preclinical activities in gene therapy by our partner Sarepta.

I will now hand over the call to Donato, who will take us through the recently announced exclusive partnership agreement with Sarepta Therapeutics in gene therapy as well as the financials. Donato, please?

--------------------------------------------------------------------------------

Donato Spota, Hansa Biopharma AB (publ) - CFO & Senior VP [3]

--------------------------------------------------------------------------------

Thank you, Sam. Please turn to Slide 8. As highlighted by Soren, the Sarepta agreement was the first partnership in gene therapy for Hansa Biopharma and serves as a landmark milestone for the company, as we expand our enzyme technology beyond transplantation and autoimmune diseases. This is a unique opportunity for both companies to combine efforts and use Hansa's antibody-cleaving enzyme, imlifidase, to potentially enable it to access to gene therapy for a much broader range of patients, while unlocking significant additional potential value. It is estimated that 15% to 20% of patients in each of the 2 relevant indications have preexisting neutralizing antibodies to AAV-based gene therapy, which prevents the patients from being treated.

Under the agreement, Hansa grants Sarepta an exclusive license to develop and promote imlifidase as a potential pretreatment prior to the administration of gene therapy in patients with neutralizing antibodies to AAV vectors in Duchenne muscular dystrophy and limb-girdle muscular dystrophy. Sarepta will be responsible for conducting and financing all preclinical and clinical studies to develop imlifidase as a pretreatment to Sarepta's gene therapies as well as any potential subsequent regulatory approvals. Hansa will support the development program with know-how, existing data and regulatory assets, as well as by supplying imlifidase for development purposes free of charge.

The significant potential value of the partnership is also reflected in the economics. Under the terms of the license, Hansa received USD 10 million upfront and will be eligible for up to USD 397.5 million in payments upon achievement of certain predefined development, regulatory and sales milestones, with sales milestones accounting for the majority of such potential payments. In addition, Hansa will book all sales of imlifidase and earn high single-digit to mid-teens royalties on Sarepta's incremental gene therapy sales and treating Nabs-positive patients, enabled through pretreatment with imlifidase.

Please turn to Slide 9. With the continuing advancements we have made across our operations, we have also seen investments increasing during the first half of this year with regard to our pipeline as well as related to the commercial preparations, as we are getting ready to launch. For the first half of 2020, our SG&A expenses amounted to SEK 88 million, compared to SEK 68 million in the same period 2019.

Our investments in R&D amounted to SEK 106 million for the first half of 2020, which is up SEK 18 million compared to the first half of 2019. Investing in R&D and our medical affairs activities remain a constant priority for short-, mid- and long-term value creation. The net loss for the first half of 2020 amounted to SEK 193 million, compared to SEK 155 million for the same period 2019.

Please turn to Slide 10. Cash flow from operating activities amounted to minus SEK 199 million for the first half, compared to minus SEK 180 million for the same period a year ago. At the end of June, our cash position, including short-term investments, amounted to SEK 400 million, which is equivalent to approximately USD 40 million. Beginning of July, we substantially strengthened our cash position by successful completion of SEK 1.1 billion direct placement of 4.4 million newly issued shares. The placement was oversubscribed multiple times and included significant participation from leading life science investors in the U.S. and Europe. The net proceeds of the placing will be used to continue to develop and expand Hansa's R&D pipeline as well as to fund potential launch and commercialization of imlifidase in kidney transplantation. More specifically, the proceeds will enable us to fund the continued development of imlifidase for additional indications such as AMR, GBS and anti-GBM as well as our ongoing commercial buildup in preparation for the expected upcoming launch in Europe. And we plan to invest further in the company's development of next-generation IgG-eliminating enzymes for repeat dosing as well as fund working capital needs and general purposes. With the significant capital injection, we expect our operations to be financed into 2023.

With this, I hand back to Soren to give his final remarks.

--------------------------------------------------------------------------------

Sren Tulstrup, Hansa Biopharma AB (publ) - President & CEO [4]

--------------------------------------------------------------------------------

Thank you, Donato. Now please turn to Slide 11. Over the past year, we've made significant progress across our business and pipeline development operations. Our organization has also expanded as we continue to strengthen our R&D team and prepare for the launch of imlifidase in Europe, expected later this year. We're looking ahead to further value creation with many important milestones in 2020 and the years to come. Following the positive opinion end of June, we expect formal adoption by the European Commission and conditional approval in the third quarter. Assuming the approval is obtained, as expected, we aim to launch imlifidase in the first clinics in the fourth quarter. In the third quarter this year, we should also have the first data readout from the completed anti-GBM study. The readout from this Phase II trial will be the first high-level set of complete data from a Phase II study outside transplantation and will mark Hansa's continued advancement into new indications and therapeutic areas beyond transplantation. In the U.S., our imlifidase kidney transplant trial is expected to be initiated in Q4 this year, following the necessary protocol and ethical approvals. As highlighted earlier, the new study would enroll 45 highly sensitized patients at 10 to 15 centers in the U.S.

In summary, 2020 has already been very eventful and will continue to be an exciting year for Hansa Biopharma. We look forward to keeping you updated on the progress of our journey as we transform the company into a fully integrated, commercial-stage biopharmaceutical company that brings life-saving and life-altering therapies to patients with rare diseases and generate long-term value to our shareholders and society at large.

Please turn to Slide 11. Before we enter the Q&A session, I wanted to bring to your attention that we intend to organize a Capital Markets Day later this fall. Further details on the format and content will follow shortly, but already now, we would encourage interested institutional investors, analysts and media to save the date for the event, which is expected to take place October 29, 2020. With this, we're now ready to take your questions.

Operator, please begin.

================================================================================

Questions and Answers

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

(Operator Instructions)

Our first question comes from the line of Zoe Karamanoli from RBC.

--------------------------------------------------------------------------------

Zoe Karamanoli, RBC Capital Markets, Research Division - Analyst [2]

--------------------------------------------------------------------------------

Two questions from me, please. The first one, given the recent deal with Sarepta, I wonder if you can give us a little bit more about the discussions with other gene therapy players, and any color you have with regards to the number of companies you are in dialogue at the moment, if this number has increased post the announcement of the deal? And any indication as to how advanced are those discussions and whether we should be thinking another potential deal as the near- or longer-term event?

--------------------------------------------------------------------------------

Sren Tulstrup, Hansa Biopharma AB (publ) - President & CEO [3]

--------------------------------------------------------------------------------

Well, thanks, Zoe, for that question. So clearly, we are in discussions with a number of leading players in the field. Obviously, the challenge that Sarepta is encountering and seeing is one that other companies is dealing with as well. And so we have had these discussions ongoing for a while. They continue. At what point they will lead to the next deal to be announced, I just can't predict. There is clearly a lot of interest and so we're continuing the discussions. I can't give you any specific number as to how many we're talking to. But clearly, there's a number of companies out there that have significant challenges with neutralizing antibodies. So as you can imagine, it's certainly a reasonable number. So I guess that was the question or did I answer it conceptually.

--------------------------------------------------------------------------------

Zoe Karamanoli, RBC Capital Markets, Research Division - Analyst [4]

--------------------------------------------------------------------------------

Yes. This is fine. I understand if you can't give more details. And then the second question, from a clinical development perspective and following the recent capital raise, what are your priorities for developing imlifidase in other indications? Is the current indication the main focus? Or we should expect to hear more in additional indication? And any color you can give on the timing of this?

--------------------------------------------------------------------------------

Sren Tulstrup, Hansa Biopharma AB (publ) - President & CEO [5]

--------------------------------------------------------------------------------

So we're very privileged to have a platform that, so far, has generated very, very good results in a number of different areas, and we're pushing ahead as fast as we can now with additional capital on hand to develop imlifidase for a range of indications. Clearly, within the transplant space, kidney is not the only organ, where you would want to enable a transplant. So we're looking at other organs there. But importantly, we're looking at the autoimmune disease space as a very exciting and promising space to further develop imlifidase. As you know, we have 2 ongoing trials there, anti-GBM and Guillain-Barre syndrome, but there are certainly other diseases, where you have very strong upfront acute attacks, where dealing with that attack will be critically important. So we're looking at what can be done there with imlifidase, clearly, in gene therapy space that we're looking at, as we just discussed. And then we have preclinical activities in the oncology space. Now imlifidase is not the only molecule in development. We have the next-generation of enzymes also in preclinical development, where we are trying to develop them for repeat dosing. And that obviously, if successful, would open up a universe of diseases where repeat dosing is highly relevant.

In the autoimmune disease space, there is a number of very serious diseases, chronic autoimmune diseases, where you have fairly rapid disease progression, and then you have flares and where you would want to deal with these flares very quickly. And so if we could successfully develop a molecule that could do that to deal with these players then that will bring a lot of value, I think, to the patients. So that's certainly an area that we're looking at as well. As you know, we have our lead candidates currently getting ready for IND-enabling tox studies, and we're hoping that we can take it into the clinic in the foreseeable future.

--------------------------------------------------------------------------------

Operator [6]

--------------------------------------------------------------------------------

And the next question comes from the line of Ingrid Gafanhao from Kempen.

--------------------------------------------------------------------------------

Ingrid Gafanho, Kempen & Co. N.V., Research Division - Research Analyst [7]

--------------------------------------------------------------------------------

So as you mentioned, you just received the CHMP positive opinion for Idefirix in kidney transplantation in Europe. And we know that this is going through a conditional approval process. So have you gotten already any insight from the EMA on how the confirmatory trial should look like? Or is that something that you expect to get when the formal approval comes along?

--------------------------------------------------------------------------------

Sren Tulstrup, Hansa Biopharma AB (publ) - President & CEO [8]

--------------------------------------------------------------------------------

So it certainly has been part of the dialogue with the CHMP, what will be the design of a post approval study. So that is part of the decision that CHMP has made, and that will then be formally endorsed by -- hopefully by the commission relatively soon. And so what we overall are saying is that this will be a study that is designed to produce more of the same, right? So it will be a study where we will look at the efficacy of Idefirix to enable kidney transplants in highly sensitized patients. And the specific design, we'll get back to the elements at a later stage. But this clearly will be an important part also of the overall launch efforts because it's an excellent way to actually generate experience in relevant centers in Europe.

--------------------------------------------------------------------------------

Operator [9]

--------------------------------------------------------------------------------

(Operator Instructions) Our next question comes from the line of Maneka Mirchandaney from Evercore.

--------------------------------------------------------------------------------

Maneka Mirchandaney, Evercore ISI Institutional Equities, Research Division - Analyst [10]

--------------------------------------------------------------------------------

I just had a couple on the anti-GBM results coming up. Can you talk a bit about the expected natural history for these patients over 6 months? And what you're hoping to see on the primary endpoint? Is it the stopping of progression of patients to dialysis? Or do you think there's a potential to see some reversion on need for dialysis as well? And then given the rarity of the disease, what have been your conversations with regulatory agencies on the path forward to registration after the data as well?

--------------------------------------------------------------------------------

Sren Tulstrup, Hansa Biopharma AB (publ) - President & CEO [11]

--------------------------------------------------------------------------------

Thanks, Maneka, for those questions. So if you look at natural history, what typically happens to these patients is that 2 out of 3, approximately, will end up losing kidney function altogether and happens very, very quickly following the attack. So what we're looking for really in this study is peer signals that you can produce a better outcome if you treat with imlifidase in these patients. Potentially, you could also see a reversal, a slight reversal in those patients ending up in dialysis. But the key parameter really is can we prevent patients losing the kidney function and ending up in dialysis. So that is what we're looking at. And then you're right, I mean, this is really an ultra-rare disease affecting approximately one in a million. So you have to think long and hard about how to design a next study. We have not had extensive dialogue with the regulatory authorities yet on this. Obviously, we've had some when designing the ongoing study. But once we have the readout from that study, we will engage more broadly with regulatory authorities to discuss the path forward.

--------------------------------------------------------------------------------

Operator [12]

--------------------------------------------------------------------------------

We have a follow-up question from the line of Zoe Karamanoli.

--------------------------------------------------------------------------------

Zoe Karamanoli, RBC Capital Markets, Research Division - Analyst [13]

--------------------------------------------------------------------------------

Just one more question regarding the trial recruitment. I know you mentioned that there has been a delay due to COVID for the GBS and AMR trial. I'm wondering given the uncertainty also in the future about how COVID crisis will evolve, is there you have or you're planning to have any mitigation strategy with regards to how we can improve trial recruitment rate?

--------------------------------------------------------------------------------

Sren Tulstrup, Hansa Biopharma AB (publ) - President & CEO [14]

--------------------------------------------------------------------------------

Thanks, Zoe, for that follow-up question. Yes, we do expect a delay because, as I said, we have implemented a temporary suspension of recruitment to preserve data integrity and also for logistical reasons. But we do expect to be able to reinitiate patient enrollment now. Essentially, we have remained in ongoing contact with the trial centers, and so we should be ready to reinitiate very shortly. Clearly, we missed some opportunities, and you do have to kind of get this back top of mind in centers. But once you're there, we're hopeful that, thanks to the catch-up effect, we'll see a rapid uptake at some point, and we should then be able to, again, complete enrollment with a delay of maximum 3 to 6 months, potentially less. Potentially, we'll be able to catch up, but I can't predict that at this point.

--------------------------------------------------------------------------------

Zoe Karamanoli, RBC Capital Markets, Research Division - Analyst [15]

--------------------------------------------------------------------------------

Excerpt from:
Edited Transcript of HMED.ST earnings conference call or presentation 16-Jul-20 12:00pm GMT - Yahoo Finance